| P2093 | author name string | Julia M Dixon | |
| | Kitty Rajagopalan | |
| | Rachael L Fleurence | |
| | Mary Lou Chatterton | |
| P2860 | cites work | Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication | Q22253031 |
| | Modelling in economic evaluation: an unavoidable fact of life | Q28243908 |
| | Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group | Q28375949 |
| | Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: does it make a difference? | Q31061524 |
| | Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application | Q34025539 |
| | Bipolar disorder--costs and comorbidity | Q34442568 |
| | Health care utilization and costs among privately insured patients with bipolar I disorder | Q35041602 |
| | OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis | Q35097535 |
| | Towards a reference case for economic evaluation of osteoporosis treatments. | Q35624055 |
| | A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder | Q35684477 |
| | A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder | Q35775412 |
| | Generalisability in economic evaluation studies in healthcare: a review and case studies. | Q35950554 |
| | Bipolar depression: a new role for atypical antipsychotics? | Q36158827 |
| | Economics of atypical antipsychotics in bipolar disorder: a review of the literature | Q36519345 |
| | Clinical trial-based cost-effectiveness analyses of antipsychotic use. | Q36675837 |
| | Bias in location and selection of studies | Q41694445 |
| | Lithium in bipolar mood disorder | Q42777458 |
| | Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 |
| | The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. | Q43682742 |
| | Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial | Q44053443 |
| | Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial | Q44385585 |
| | Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. | Q44418395 |
| | A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 |
| | Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial | Q44915194 |
| | A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder | Q45237779 |
| | Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine | Q46416654 |
| | Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial | Q46494999 |
| | Relationship between initial quetiapine dose and effectiveness as reflected in subsequent mental health service use among patients with schizophrenia or bipolar disorder | Q46642578 |
| | Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | Q46681460 |
| | Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial | Q46683979 |
| | Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. | Q51951926 |
| | Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder. Psychometric performance of four self-report measures. | Q51992751 |
| | Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. | Q52024329 |
| | Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia | Q79411247 |
| | Practice guideline for the treatment of patients with bipolar disorder (revision) | Q95789383 |
| P433 | issue | 6 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | 419-428 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Primary Care Companion to the Journal of Clinical Psychiatry | Q15751574 |
| P1476 | title | Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review | |
| P478 | volume | 9 | |